Abstract
Disclosed herein is a novel use of 3,3’-dihydroxy-2’,6’-bis(p-hydroxybenzyl)-5-methoxybibenzyl (or bletinib), a salt, a solvate or an ester thereof for manufacturing a medicament suitable for the treatment of diseases and/or disorders associated with the dysregulated activation and recruitment of neutrophils, such as acute lung injury (ALI).
| Translated title of the contribution | METHODS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH DYSREGULATED ACTIVATION AND RECRUITMENT OF NEUTROPHILS |
|---|---|
| Original language | Chinese (Traditional) |
| Patent number | I775408 |
| IPC | A61K 31/05(2006.01); A61P 11/00(2006.01) |
| State | Published - 21 08 2022 |
Bibliographical note
公開公告號: I775408Announcement ID: I775408